DUBLIN, August 20, 2025 — Leads & Copy — Trinity Biotech plc (Nasdaq: TRIB) announced that it has received approval from in-country healthcare authorities to begin offshore and outsourced manufacturing of its TrinScreen™ HIV rapid test. The move is expected to expand gross margins, free up working capital, and enhance scalability.
The approval allows Trinity Biotech to transition production from in-house operations to a cost-effective, outsourced model, while maintaining product integrity and regulatory compliance. Manufacturing has already commenced under this new model.
According to John Gillard, President and CEO, the approval is a major step that unlocks cost efficiencies and enhances scalability.
Susan O’Connor, Trinity Biotech plc, (353)-1-2769800
Dave Gentry, CEO, RedChip Companies Inc., (1)-407-644-4256, (1)-800-RED-CHIP (733-2447), TRIB@redchip.com
Source: Trinity Biotech
